RooLife Group Ltd (ASX:RLG) reports a remarkable 144% jump in Q2 FY25 sales revenue, driven by new online stores and strategic market entries into China and India. The company’s own branded health and wellness products are central to its growth strategy.
Elixinol Wellness delivered a standout Q4 FY24 performance with a 71% jump in cash receipts and a 64% rise in revenue, driven by key acquisitions and operational efficiencies. The company edges closer to EBITDA break-even, setting the stage for growth in 2025.
EVE Health Group has completed the sale of its Robyndale tea tree property and relaunched its postbiotic concentrate range, signaling a strategic shift towards innovation and growth in the Australian market.
Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with imminent UK export approvals and planned European manufacturing.